{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T11:31:48Z","timestamp":1771327908517,"version":"3.50.1"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Crohn's and Colitis"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1016\/j.crohns.2011.10.012","type":"journal-article","created":{"date-parts":[[2011,11,23]],"date-time":"2011-11-23T22:30:14Z","timestamp":1322087414000},"page":"483-487","source":"Crossref","is-referenced-by-count":11,"title":["Pneumocystosis in a patient with Crohn's disease treated with combination therapy with adalimumab"],"prefix":"10.1093","volume":"6","author":[{"given":"Ana L.","family":"Desales","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Mendez-Navarro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis J.","family":"M\u00e9ndez-Tovar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nayeli X.","family":"Ortiz-Olvera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Garret","family":"Cullen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joaqu\u00edn","family":"Ocampo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Willian","family":"Lemus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amina E.","family":"Tun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arturo","family":"Mayoral-Zavala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margarita","family":"Dehesa-Violante","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","reference":[{"key":"10.1016\/j.crohns.2011.10.012_bb0005","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/00000441-200101000-00009","article-title":"Pneumocystis carinii pneumonia in patients without HIV infection","volume":"321","author":"Russian","year":"2001","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.crohns.2011.10.012_bb0010","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMra032588","article-title":"Pneumocystis pneumonia","volume":"350","author":"Thomas","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.crohns.2011.10.012_bb0015","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/1471-2334-10-126","article-title":"Risk of pneumocystosis after early discontinuation of prophylaxis among HIV-infected patients receiving highly active antiretroviral therapy","volume":"10","author":"Cheng","year":"2010","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.crohns.2011.10.012_bb0020","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s00535-006-1995-7","article-title":"Inflammatory bowel disease: past, present, and future","volume":"42","author":"Sands","year":"2007","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.crohns.2011.10.012_bb0025","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/ajg.2008.168","article-title":"Management of Crohn's disease in adults","volume":"104","author":"Lichtenstein","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.crohns.2011.10.012_bb0030","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1053\/j.gastro.2004.02.070","article-title":"Optimizing anti-TNF treatment in inflammatory bowel disease","volume":"126","author":"Rutgeerts","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.crohns.2011.10.012_bb0035","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine or combination therapy for Crohn's disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.crohns.2011.10.012_bb0040","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1097\/00007611-198306000-00030","article-title":"Atypical Pneumocystis carinii pneumonia: the potential hazards of empiric treatment","volume":"76","author":"Peters","year":"1983","journal-title":"South Med J"},{"key":"10.1016\/j.crohns.2011.10.012_bb0045","first-page":"1438","article-title":"Pneumocystis carini pneumonia following initiation of infliximab and azathioprine therapy with Crohn's disease","volume":"49","author":"Seddik","year":"2004","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.crohns.2011.10.012_bb0050","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1007\/s10620-006-9250-x","article-title":"Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases","volume":"52","author":"Kaur","year":"2007","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.crohns.2011.10.012_bb0055","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.gtc.2010.08.018","article-title":"Tumor necrosis factor \u03b1 monoclonal antibodies in the treatment of inflammatory bowel disease: clinical practice pharmacology","author":"Lee","year":"2010","journal-title":"Gastroenterol Clin North Am"},{"key":"10.1016\/j.crohns.2011.10.012_bb0060","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0025-6196(11)60839-2","article-title":"Fungal infections complicating tumor necrosis factor \u03b1 blockade therapy","volume":"83","author":"Tsiodras","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.crohns.2011.10.012_bb0065","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1177\/1756283X09356872","article-title":"Current directions of biologic therapies in inflammatory bowel diseases","volume":"3","author":"Reenaers","year":"2010","journal-title":"Ther Adv Gastroenterol"},{"key":"10.1016\/j.crohns.2011.10.012_bb0070","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","article-title":"Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease : the CHARM trial","volume":"132","author":"Colombel","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.crohns.2011.10.012_bb0075","first-page":"265","article-title":"Consenso mexicano sobre el uso de agentes anti-TNF-\u03b1 en el tratamiento de la enfermedad inflamatoria intestinal","volume":"74","author":"Yamamoto-Furusho","year":"2009","journal-title":"Rev Gastroenterol Mex"},{"key":"10.1016\/j.crohns.2011.10.012_bb0080","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1053\/j.gastro.2007.05.006","article-title":"American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21\u201323, 2006","volume":"133","author":"Clark","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.crohns.2011.10.012_bb0085","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/j.1478-3231.2010.02332.x","article-title":"Hepatitis B Screening, prophylaxis and reactivation in the era of rituximab-based chemotherapy","volume":"31","author":"M\u00e9ndez-Navarro","year":"2011","journal-title":"Liver Int"},{"key":"10.1016\/j.crohns.2011.10.012_bb0090","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1097\/MEG.0b013e3283329d13","article-title":"Subfulminant hepatitis B during treatment with adalimumab in a patient with rheumatorid arthritis and chronic hepatitis B","volume":"22","author":"Verhelst","year":"2010","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.crohns.2011.10.012_bb0095","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1002\/ibd.20956","article-title":"Adalimumab safety in global clinical trials of patients with Crohn's disease","volume":"15","author":"Colombel","year":"2009","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.crohns.2011.10.012_bb0100","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/art.24283","article-title":"Pneumocystis jiroveci pneumonia in patients with Rheumatoid Arthritis treated with infliximab: a retrospective review and case\u2013control study of 21 patients","volume":"61","author":"Komano","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.crohns.2011.10.012_bb0105","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1007\/s10620-006-9575-5","article-title":"Pneumocystis pneumonia during combined therapy of infliximab, corticosteroid and azathioprine in a patient with Crohn's disease","volume":"52","author":"Itaba","year":"2007","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.crohns.2011.10.012_bb0110","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1111\/j.1440-1746.2010.06407.x","article-title":"Serious infections in patients with inflammatory bowel disease receiving anti-tumor-necrosis-factor-alpha therapy: an Australian and New Zealand experience","volume":"25","author":"Lawrance","year":"2010","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.crohns.2011.10.012_bb0115","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.cgh.2010.09.026","article-title":"Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease","volume":"9","author":"Cottone","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.crohns.2011.10.012_bb0120","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1586\/14787210.3.3.435","article-title":"Management of Pneumocystis pneumonia in patients with inflammatory disorders","volume":"3","author":"Roblot","year":"2005","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.crohns.2011.10.012_bb0125","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1093\/jac\/dkp372","article-title":"Clinical efficacy of first-and second-line treatments for HIV-associated Pneumocystis jirovecii pneumonia: a tri-centre cohort study","volume":"64","author":"Helweg-Larsen","year":"2009","journal-title":"JAC"},{"key":"10.1016\/j.crohns.2011.10.012_bb0130","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.crohns.2009.02.010","article-title":"European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease","volume":"3","author":"Rahier","year":"2009","journal-title":"J Crohns Colitis"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1873994611003102?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1873994611003102?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/6\/4\/483\/1180871\/6-4-483.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,14]],"date-time":"2024-04-14T23:51:46Z","timestamp":1713138706000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-lookup\/doi\/10.1016\/j.crohns.2011.10.012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["S1873994611003102"],"URL":"https:\/\/doi.org\/10.1016\/j.crohns.2011.10.012","relation":{},"ISSN":["1873-9946"],"issn-type":[{"value":"1873-9946","type":"print"}],"subject":[],"published":{"date-parts":[[2012,5]]}}}